Trombetta Dominick, Garrett Kathleen, Harrison Marissa
Department of Pharmacy Practice, Wilkes University Nesbitt School of Pharmacy College of Pharmacy and Nursing, Wilkes-Barre, Pennsylvania.
Consult Pharm. 2013 Oct;28(10):661-9. doi: 10.4140/TCP.n.2013.661.
New-onset urinary retention can typically be explained by the use of the routine normally suspected medications (e.g., anticholinergics, antihistamines). However, selective serotonin-reuptake inhibitors are not typically presumed as the cause of acute urinary retention (AUR). The following case describes the introduction of escitalopram in a patient and the subsequent development of AUR. Medical causes of urinary retention had been ruled out, and ipratropium was initially suspected to be the cause of urinary difficulties and was discontinued. However, the retention persisted four days after suspending the ipratropium. Normal micturition resumed only after stopping the escitalopram without further need for catheterization. Escitalopram may cause rare cases of AUR and may often times be overlooked possibly because of the paucity of reporting.
新发尿潴留通常可以用常规怀疑的药物（如抗胆碱能药、抗组胺药）的使用来解释。然而，选择性5-羟色胺再摄取抑制剂通常不被认为是急性尿潴留（AUR）的病因。以下病例描述了一名患者开始使用艾司西酞普兰后继而发生急性尿潴留的情况。尿潴留的医学原因已被排除，异丙托溴铵最初被怀疑是排尿困难的原因并已停用。然而，停用异丙托溴铵四天后尿潴留仍持续存在。仅在停用艾司西酞普兰后才恢复正常排尿，无需进一步导尿。艾司西酞普兰可能导致罕见的急性尿潴留病例，并且由于报告较少，可能常常被忽视。
